Galectin-13 and Laeverin Levels Interfere with Human Fetoplacental Growth

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 27

PMID 38928055

Authors

Mario Vincze

Janos Sikovanyecz Jr

Imre Foldesi

Andrea Suranyi

Szabolcs Varbiro

Gabor Nemeth

Janos Sikovanyecz

Zoltan Kozinszky

Affiliations

Soon will be listed here.

Abstract

Galectin-13 (Gal-13) is predominantly produced by the syncytiotrophoblast, while laeverin is expressed on the outgrowing extravillous trophoblast, and both are thought to be biomarkers of preeclampsia. The aim of this study was to assess the correlation between concentrations of Gal-13 and laeverin measured in maternal serum and amniotic fluid at 16-22 weeks of gestation and the sonographic assessment of the fetoplacental measurements. Fetal biometric data and placental volume and perfusion indices were measured in 62 singleton pregnancies. Serum and amniotic levels of Gal-13 and laeverin levels were measured using a sandwich ELISA. Both amniotic fluid and serum Gal-13 levels expressed a negative correlation to the plasma laeverin level in mid-pregnancy. Serum laeverin level correlated positively with the gestational length at delivery (β = 0.39, < 0.05), while the amniotic laeverin level correlated well with the abdominal circumference of the fetus (β = 0.44, < 0.05). Furthermore, laeverin level in the amnion correlated positively with the estimated fetal weight (β = 0.48, < 0.05) and with the placental volume (β = 0.32, < 0.05). Logistic regression analyses revealed that a higher circulating Gal-13 level represents a slightly significant risk factor (OR: 1.01) for hypertension-related diseases during pregnancy. It is a novelty that laeverin can be detected in the amniotic fluid, and amnion laeverin concentration represents a potential biomarker of fetoplacental growth.

Citing Articles

Amniotic Fluid and Maternal Serum Laeverin Levels and Their Correlations with Fetal Size and Placental Volume in Second Trimester of Pregnancy-A Prospective Cross-Sectional Study.

Sikovanyecz Jr J, Gullo G, Vincze M, Foldesi I, Nemeth G, Suranyi A Diagnostics (Basel). 2025; 15(3).

PMID: 39941247 PMC: 11816444. DOI: 10.3390/diagnostics15030317.

References

Nystad M, Sitras V, Nordbakken C, Pedersen M, Acharya G . Laeverin protein expression in normal and preeclamptic placentas using tissue microarray analysis. Acta Obstet Gynecol Scand. 2018; 97(5):536-544. DOI: 10.1111/aogs.13304. View

Lai P, Wang Y, Welsh A . Reproducibility of regional placental vascularity/perfusion measurement using 3D power Doppler. Ultrasound Obstet Gynecol. 2010; 36(2):202-9. DOI: 10.1002/uog.7608. View

Nystad M, Sitras V, Flo K, Widnes C, Vartun A, Wilsgaard T . Longitudinal reference ranges for maternal plasma laeverin, and its role as a potential biomarker of preeclampsia. BMC Pregnancy Childbirth. 2016; 16(1):377. PMC: 5124228. DOI: 10.1186/s12884-016-1156-9. View

Sammar M, Nisemblat S, Fleischfarb Z, Golan A, Sadan O, Meiri H . Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta. 2011; 32 Suppl:S30-6. DOI: 10.1016/j.placenta.2010.09.006. View

Than N, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z . Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 2004; 271(6):1065-78. DOI: 10.1111/j.1432-1033.2004.04004.x. View

Balogh A, Toth E, Romero R, Parej K, Csala D, Szenasi N . Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. Front Immunol. 2019; 10:1240. PMC: 6593412. DOI: 10.3389/fimmu.2019.01240. View

Sammar M, Drobnjak T, Mandala M, Gizurarson S, Huppertz B, Meiri H . Galectin 13 (PP13) Facilitates Remodeling and Structural Stabilization of Maternal Vessels during Pregnancy. Int J Mol Sci. 2019; 20(13). PMC: 6651626. DOI: 10.3390/ijms20133192. View

Vokalova L, Balogh A, Toth E, van Breda S, Schafer G, Hoesli I . Placental Protein 13 (Galectin-13) Polarizes Neutrophils Toward an Immune Regulatory Phenotype. Front Immunol. 2020; 11:145. PMC: 7028707. DOI: 10.3389/fimmu.2020.00145. View

Sitras V, Paulssen R, Gronaas H, Leirvik J, Hanssen T, Vartun A . Differential placental gene expression in severe preeclampsia. Placenta. 2009; 30(5):424-33. DOI: 10.1016/j.placenta.2009.01.012. View

10.

Suranyi A, Altorjay A, Kaiser L, Nyari T, Nemeth G . Evaluation of placental vascularization by three-dimensional ultrasound examination in second and third trimester of pregnancies complicated by chronic hypertension, gestational hypertension or pre-eclampsia. Pregnancy Hypertens. 2017; 8:51-59. DOI: 10.1016/j.preghy.2017.03.004. View

11.

Bhati T, Ray A, Arora R, Siraj F, Parvez S, Rastogi S . Galectins are critical regulators of cytokine signalling at feto-maternal interface in infection-associated spontaneous preterm birth. Placenta. 2023; 138:10-19. DOI: 10.1016/j.placenta.2023.04.015. View

12.

Fujiwara H . Membrane-bound peptidases regulate human extravillous trophoblast invasion. Placenta. 2007; 28 Suppl A:S70-5. DOI: 10.1016/j.placenta.2007.01.005. View

13.

Molnar A, Suranyi A, Nyari T, Nemeth G, Pal A . Examination of placental three-dimensional power Doppler indices and perinatal outcome in pregnancies complicated by intrauterine growth restriction. Int J Gynaecol Obstet. 2015; 129(1):5-8. DOI: 10.1016/j.ijgo.2014.10.035. View

14.

Nystad M, Sitras V, Larsen M, Acharya G . Placental expression of aminopeptidase-Q (laeverin) and its role in the pathophysiology of preeclampsia. Am J Obstet Gynecol. 2014; 211(6):686.e1-31. DOI: 10.1016/j.ajog.2014.06.047. View

15.

Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H . Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther. 2008; 24(3):230-6. DOI: 10.1159/000151344. View

16.

Demir R, Seval Y, Huppertz B . Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem. 2007; 109(4):257-65. DOI: 10.1016/j.acthis.2007.02.008. View

17.

Khalil A, Cowans N, Spencer K, Goichman S, Meiri H, Harrington K . First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 2009; 29(8):781-9. DOI: 10.1002/pd.2287. View

18.

Pijnenborg R, Bland J, Robertson W, Brosens I . Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy. Placenta. 1983; 4(4):397-413. DOI: 10.1016/s0143-4004(83)80043-5. View

19.

Dahlstrom B, Romundstad P, Oian P, Vatten L, Eskild A . Placenta weight in pre-eclampsia. Acta Obstet Gynecol Scand. 2008; 87(6):608-11. DOI: 10.1080/00016340802056178. View

20.

Vasilache I, Carauleanu A, Socolov D, Matasariu R, Pavaleanu I, Nemescu D . Predictive performance of first trimester serum galectin-13/PP-13 in preeclampsia screening: A systematic review and meta-analysis. Exp Ther Med. 2022; 23(6):370. PMC: 9019605. DOI: 10.3892/etm.2022.11297. View